Adaptive Biotechnologies Launches Enhanced Assay Reports for Patients with CLL

Adaptive Biotechnologies launched an enhanced version of its clonoSEQ^® B-cell Clonality report. It will now feature the immunoglobulin heavy chain variable gene mutation status for patients with chronic lymphocytic leukemia (CLL).

The clonoSEQ assay was approved by the U.S. Food and Drug Administration to detect and monitor minimal residual disease in the blood or bone marrow of patients with CLL.

For more information on the clonoSEQ assay and its enhancements, read the Adaptive Biotechnologies announcement.

Posted 10/19/2021